OncoMatch/Clinical Trials/NCT07456878
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
Is NCT07456878 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies FET-PET/MRI for pituitary adenoma.
Treatment: FET-PET/MRI — The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
Check if I qualifyEligibility summary
For patients with Pituitary Adenoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Mayo Clinic · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify